![2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole(CAS#172152-36-2) Featured Image](https://www.xinchem.com/uploads/benzoimidazole.png)
2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole(CAS#172152-36-2)
2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole(CAS#172152-36-2)
pharmachologic effect
Ilaprazole is a proton pump inhibitor that specifically acts on the parietal cells of the gastric mucosa. It enters the secretory tubule of parietal cells, converts into the active form of sulfinamide in this high-acid environment, and irreversibly combines with the sulfhydryl group of the proton pump through disulfide bonds to generate a complex of sulfinamide and proton pump, thereby inhibiting the activity of the proton pump, blocking the last step of gastric acid secretion, and producing the effect of inhibiting gastric acid secretion.
Clinical application
It is mainly used for the treatment of acid-related diseases such as duodenal ulcer and reflux esophagitis. For patients with excessive gastric acid secretion, resulting in damage to the gastric mucosa and duodenal mucosa, ilaprazole can inhibit gastric acid secretion, increase the pH value in the stomach and duodenum, and create a good environment for the repair of the damaged mucosa, thereby alleviating symptoms such as heartburn, acid reflux, and epigastric pain.
security
During use, some adverse reactions may occur, such as diarrhea, dizziness, headache, abnormal liver function, etc., but the general symptoms are relatively mild and can be tolerated by most patients. However, caution is required in patients with severe hepatic impairment, as the metabolism of the drug in the body may be affected, increasing the risk of adverse effects.
Synthesis method
Generally, 2-chloromethyl-4-methoxy-3-methylpyridine is used as the starting material, and the corresponding thioether is formed by reaction with mercaptan, and then sulfoxide is obtained by oxidation reaction, and then a series of steps such as condensation reaction with 5-pyrrole-1H-benzimidazole are carried out to finally synthesize ilaprazole.
Application
Ilaprazole is a novel proton pump inhibitor (PPI) that selectively and irreversibly inhibits the gastric H⁺,K⁺-ATPase, the final step of gastric acid secretion. It is clinically approved in China and South Korea for the treatment of acid-related gastrointestinal disorders, including duodenal ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease. Ilaprazole offers distinct advantages over other PPIs: a longer plasma half-life (3.9 hours) enabling superior 24-hour intragastric pH control, a broader therapeutic dose range with favorable safety, and a metabolism largely independent of CYP2C19, resulting in low inter-individual variability and predictable efficacy across diverse patient populations. Beyond its established anti-secretory role, recent research has identified that ilaprazole also inhibits cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo. As an active pharmaceutical ingredient (API) and a certified reference standard, Ilaprazole is essential for pharmaceutical R&D, including analytical method development (AMD), method validation (AMV), quality control (QC) for ANDA filings, impurity profiling, and commercial production of generic and innovator PPI formulations. Its high-purity grade is also indispensable for preclinical studies, metabolic profiling, and clinical pharmacology research. Xinchem offers custom synthesis, custom chemical synthesis, and contract manufacturing of high-purity Ilaprazole with flexible scaling from R&D to commercial tons. Contact us today for a competitive quote and reliable global supply.
